Adaptive is pleased to announce the appointment of Sean Nolan as Chief Technology Officer and the newest member of the Company’s expanding Executive Leadership Team. Mr. Nolan’s hire, the second management hire this month, represents Adaptive’s continued commitment to incorporating state-of-the-art data solutions into its suite of immunosequencing products and services.
Study published in Clinical Cancer Research and co-led by Adaptive Biotechnologies and the University of Washington demonstrates clinical utility of Next Generation Immune Profiling
Adaptive is pleased to announce the appointment of Dean Schorno, CPA,. as Chief Financial Officer and the newest member of the Company’s expanding Executive Leadership Team.
Adaptive and its collaborators will present data supporting the clinical application of immunosequencing in diagnosing and monitoring T cell lymphomas at the 2014 Annual Meeting of the American Society of Clinical Oncology.
Adaptive Biotechnologies Corporation CEO, Chad Robins, highlights today the companies’ work in cancer immunotherapy at the “What’s Hot in Cancer Immunotherapy” event hosted by Xconomy at the Fred Hutchinson Cancer Research Center.
Adaptive Biotechnologies, a Seattle startup that focuses on scouring the genetic makeup of the immune system to help fight cancer and other diseases, said Monday it has raised an eye-popping $105 million in funding to boost its research and commercial efforts. Read full article at Times Website
Adaptive announced today the completion of the Company’s Series C financing round and the completion of a newly created Series D round with a $105 million investment from Viking Global Investors. This investment will enable the Company to expand globally its preeminent immunosequencing research platform and downstream validated clinical diagnostic products.
Adaptive CEO Chad Robins speaking today at “The Future of Healthcare in Washington” conference beginning at 1PM. His talk is titled “How Genomics is Enabling Diagnostics that will Change Clinical Practice.”
Julie Rubinstein, Adaptive’s SVP of Business Development, will speak at Bloomberg’s State of Health Care 2014 Conference in New York City. She will participate on an expert panel entitled Innovation in Healthcare, which will feature the growth and promise of cancer immunotherapy.
Adaptive announced today that Peter Neupert and Rob Rosen (pictured at left) will join its Board of Directors to strengthen its healthcare distribution system and software expertise and to add the financial experience necessary for commercialization.